Myo-Inositol Ineffective for Preventing Retinopathy of Prematurity

In a randomized placebo-controlled trial, myo-inositol given every 12 hours for up to 10 weeks did not reduce ROP or mortality in extremely premature infants.

Myo-inositol, a surfactant component, has been thought, but not proven, to reduce the risk for the serious complication of retinopathy of prematurity (ROP) in premature infants.

To test its potential benefit in this setting, investigators have conducted a randomized, double-blind, placebo-controlled trial that assessed the development of ROP and mortality rates in 638 premature infants (<28 weeks' gestation) who were given either myo-inositol (40 mg/kg) or placebo every 12 hours for up to 10 weeks.

Type 1 ROP (defined as meeting criteria for intervention to prevent retinal detachment) or death was more common among infants receiving myo-inositol versus placebo (29% vs. 21%; P=0.01). A prespecified exploratory analysis found that death prior t…

Reviewing Author

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

Myo-Inositol Ineffective for Preventing Retinopathy of Prematurity

Topics

Reviewing Author